ProstaLund AB
ProstaLund AB (publ), a medical technology company, develops, manufactures, and sells urological devices and treatments in Sweden and internationally. It offers CoreTherm, a heat treatment for benign prostate enlargement; CoreFlow, a temporary prostate stent; Oruflow, a urine flow meter; and Schelin Catheter, a medical device intended for intraprostatic and periprostatic injection of legally mark… Read more
ProstaLund AB (PLUN) - Total Liabilities
Latest total liabilities as of June 2025: Skr11.30 Million SEK
Based on the latest financial reports, ProstaLund AB (PLUN) has total liabilities worth Skr11.30 Million SEK as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
ProstaLund AB - Total Liabilities Trend (2012–2024)
This chart illustrates how ProstaLund AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
ProstaLund AB Competitors by Total Liabilities
The table below lists competitors of ProstaLund AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Transpaco Ltd
JSE:TPC
|
South Africa | ZAC547.18 Million |
|
nDatalyze Corp
OTCQB:NDATF
|
USA | $18.79K |
|
ATLANTICUS HLDGS
BE:YCC
|
Germany | €2.59 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down ProstaLund AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProstaLund AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProstaLund AB (2012–2024)
The table below shows the annual total liabilities of ProstaLund AB from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr6.46 Million | -36.80% |
| 2023-12-31 | Skr10.22 Million | +9.18% |
| 2022-12-31 | Skr9.36 Million | +16.61% |
| 2021-12-31 | Skr8.02 Million | +46.29% |
| 2020-12-31 | Skr5.49 Million | +31.95% |
| 2019-12-31 | Skr4.16 Million | -35.50% |
| 2018-12-31 | Skr6.45 Million | +55.34% |
| 2017-12-31 | Skr4.15 Million | -6.15% |
| 2016-12-31 | Skr4.42 Million | +13.10% |
| 2015-12-31 | Skr3.91 Million | -1.54% |
| 2014-12-31 | Skr3.97 Million | -9.30% |
| 2013-12-31 | Skr4.38 Million | +96.90% |
| 2012-12-31 | Skr2.22 Million | -- |